HTT and juvenile Huntington disease: Nonetheless, several ASOs are being investigated in HD models, and an ASO targeting human huntingtin, IONIS-HTTRX (tominersen), has entered human clinical trials (NCT02519036—Safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-HTTRX in patients with early manifest Huntington’s disease) [69].